Aspen Pharmacare Eyes Canada GLP-1 Generic Approval by September

2026-03-03 - 17:43

(Bloomberg) — Africa’s largest drugmaker expects to get approval in Canada for its generic GLP-1 obesity treatment by September, potentially giving it an early start in a key market after Novo Nordisk A/S’s Ozempic patent expired. Read More